Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
CNS Pharmaceuticals, Inc. - Common Stock
(NQ:
CNSP
)
4.890
+0.170 (+3.60%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 12, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about CNS Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
...
9
10
11
12
13
14
15
16
Next >
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Present at H.C. Wainwright Global Investment Conference
May 24, 2022
Via
Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Berubicin Among Most Powerful of Chemotherapy Drugs
May 23, 2022
Via
Investor Brand Network
Lantern Pharma to Host Glioblastoma Multiforme Webinar to Mark Brain Tumor Awareness Month
May 19, 2022
Via
Investor Brand Network
Topics
Artificial Intelligence
BioMedNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Abstract to be Presented at American Society of Clinical Oncology 2022 Annual Meeting
May 18, 2022
Via
Investor Brand Network
Updated Guidelines Shed Light on Using Radiation Against Brain Metastases
May 16, 2022
Via
Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Q1 2022 Financial, Corporate Update
May 16, 2022
Via
Investor Brand Network
Researchers Develop Models to Better Understand Brain Cancer Metastasis
May 11, 2022
Via
Investor Brand Network
Investor Event Turns Spotlight on Novel Brain Cancer Drug Candidate Global Trial Under Way by CNS Pharmaceuticals, Inc. (NASDAQ: CNSP)
May 11, 2022
Via
Investor Brand Network
Study Finds Strong Link Between Hormone Drug, Growth of Brain Tumors
May 06, 2022
Via
Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Berubicin Demonstrating ‘Encouraging Promise in Treatment of GBM’
May 05, 2022
Via
Investor Brand Network
Johns Hopkins Researchers Receive Millions for New Cancer Research Projects
May 03, 2022
Via
Investor Brand Network
Researchers May Have Found New Way to Slow Progression of Cancer
May 02, 2022
Via
Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Secures Approval from Ethics Committee and Competent Authority in Spain for Potentially Pivotal Study
April 28, 2022
Via
Investor Brand Network
Plants Could Unlock Future Cancer Therapies
April 25, 2022
Via
Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Focused on Advancing Research on Treatments for GBM, Other Cancers
April 22, 2022
Via
Investor Brand Network
JTC Team Announces Continuation of its Virtual Investor Spotlight Series with NASDAQ: AEZS, NASDAQ: CNSP, and NASDAQ: AREC
April 13, 2022
- Live video webcast events on Thursday, April 14 at 10 AM ET, 11:30 AM ET and 1 PM ET - FRENCHTOWN, NJ / ACCESSWIRE / April 13, 2022 / JTC Team ("JTC"), a fully integrated corporate communications and...
From
JTC Team, LLC
Via
AccessWire
European Regulatory Approvals Help CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Advance ‘Potentially Pivotal’ Study of Novel Brain Cancer Drug
April 13, 2022
Via
Investor Brand Network
CNS Pharmaceuticals (NASDAQ: CNSP) to Participate in Upcoming Virtual Investor Event
April 12, 2022
Via
Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Participate in Upcoming Virtual Investor Event
April 12, 2022
Via
Investor Brand Network
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Leading the Charge toward Advancing Research on Treatments for Primary and Metastatic Central Nervous System Cancers
April 11, 2022
Via
Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Secures Approval from France EC and ANSM Competent Authority for Potentially Pivotal Study of Berubicin
April 06, 2022
Via
Investor Brand Network
CNS Pharmaceuticals (NASDAQ: CNSP) Receives Key Approval for Pivotal Study of Berubicin
April 06, 2022
Via
Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Receives Key Approval for Pivotal Study of Berubicin
April 05, 2022
Via
Investor Brand Network
CNS Pharmaceuticals (NASDAQ: CNSP) CEO Shares Company Highlights at Virtual Growth Conference
April 05, 2022
Via
Investor Brand Network
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) CEO John Climaco Shares Company Highlights, Goals at 2022 Virtual Growth Conference Presented by Maxim Group LLC
April 04, 2022
Via
Investor Brand Network
CNS Pharmaceuticals (NASDAQ: CNSP) to Participate at 2022 Virtual Growth Conference
March 24, 2022
Via
Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Participate at the 2022 Virtual Growth Conference
March 23, 2022
Via
Investor Brand Network
CNS Pharmaceuticals (NASDAQ: CNSP) CEO Discusses Milestone in Advancing Berubicin
March 18, 2022
Via
Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO Discusses Significant Milestone in Advancing Berubicin
March 17, 2022
Via
Investor Brand Network
CNS Pharmaceuticals (NASDAQ: CNSP) Reiterates Progress for Lead Product Candidate
March 10, 2022
Via
Investor Brand Network
< Previous
1
2
...
9
10
11
12
13
14
15
16
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.